Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2011-002469-39-NL
EUCTR2011-002469-39-NL
Active, not recruiting
Not Applicable

DIAbetes-PREvention Trial - DiaPreT

Isala Klinieken0 sitesJune 1, 2011
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsPatients who are candidates for cardiac rehabilitation after documented coronairy artery disease (PCI or CABG in stable CAD, or post STEMI and post non-STEMI), who have pre-diabetesMedDRA version: 14.1Level: LLTClassification code 10064346Term: STEMISystem Organ Class: 100000004849MedDRA version: 14.1Level: LLTClassification code 10036482Term: Pre-diabeticSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Patients who are candidates for cardiac rehabilitation after documented coronairy artery disease (PCI or CABG in stable CAD, or post STEMI and post non-STEMI), who have pre-diabetes
Sponsor
Isala Klinieken
Status
Active, not recruiting
Last Updated
12 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 1, 2011
End Date
TBD
Last Updated
12 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Isala Klinieken

Eligibility Criteria

Inclusion Criteria

  • •Inclusion criteria
  • ••Patients admitted with coronairy artery disease (PCI or CABG in stable CAD, or post STEMI and post non\-STEMI) (inclusion within 2 month after admission)
  • •Age \= 18 years
  • •Elevated HbA1c levels (HbA1c \> 5\.8% or \> 40 mmol/mol) on admission
  • •Access to a computer with internet connection
  • •Written informed consent
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range: 0
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 39

Exclusion Criteria

  • •Exclusion criteria
  • •Known diabetics, with or without anti\-diabetic medication
  • •Contra\-indications for Metformine use as stated in the medication registration
  • •Life Expectancy \<1 yr
  • •Physical limitations/restrictions for participation in exercise programme or exercise testing
  • •Fasting plasma glucose \= 7\.0 mmol/l or HbA1c \= 53

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 4
DIAbetes-PREvention Trialpre-diabeticiHeart problemspre-diabetics10011082
NL-OMON38088Isala Klinieken78
Suspended
Not Applicable
DIAbetes-PREvention Trial.Coronary artery disease (CAD): PCI or CABG in stable CAD, or post STEMI and post non-STEMI, Cardiac rehabilitation , Diabetes Mellitus
NL-OMON21355Isala Klinieken, te ZwolleMaatschap Cardiologie, Interne en sportgeneeskunde, Isala Klinieken.78
Not yet recruiting
Phase 4
Prevention of onset of diabetes with life style modifications prescribed exercises prescribed diet yoga and drug therapy with metformin if neededHealth Condition 1: null- Type 2 diabetes mellitus
CTRI/2011/09/002009Department of Science and Technology Government of India200
Completed
Not Applicable
Early Diabetes Intervention TrialImpaired glucose toleranceNutritional, Metabolic, EndocrineDiabetes
ISRCTN96631607Bayer plc and Merck-Lipha (UK)631
Not yet recruiting
Phase 2
Pilot Clinical Trial for Treatment of Diabetic Foot Ulcers with Dietary Nano-formulated Phytochemicalsdiabetic foot ulcersMetabolic and Endocrine - Diabetes
ACTRN12610000565044CamMedica, Ltd.35